StocksMedium•9 November 2026•
1 min read
CRISPR Therapeutics Stock Eyes Gains as Gene Therapy Cuts Triglycerides by 63%
Key Facts
1A single-course treatment with CTX310 produced a 63% mean reduction in triglycerides in patients with severe hypertriglyceridemia.
CRISPR Therapeutics reported positive Phase 1b clinical data for its gene-editing therapy CTX310, where a single-course treatment produced a 63% mean reduction in triglycerides in patients with severe hypertriglyceridemia. GlobeNewswire reported that the findings, presented at the AHA Scientific Sessions 2026, also demonstrated a 65% reduction in circulating ANGPTL3 from baseline levels.
CRISPR Therapeutics, trading under the ticker CRSP, closed at $50.07 on November 6, 2026, with a daily session range between $48.41 and $50.27. The investigational therapy utilizes in vivo CRISPR/Cas9 gene editing to target cardiovascular conditions and has recently received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.